Successful cochlear implant surgery for four-year-old Angelo aids hearing, part of a charitable initiative by Care and Share Foundation.

Is this drop a warning sign? The post After falling 43% in a week, are Cochlear shares now a buy? appeared first on The ...

The Food and Drug Administration on Thursday approved Regeneron’s Otarmeni, the first gene therapy for genetic hearing loss ...

Key Takeaways Otarmeni, a gene therapy targeting a specific mutation that causes profound deafness, now has U.S. Food and ...

A bruising two-day stretch for the S&P/ASX 200 Health Care Index has underscored growing fragility in the sector, with ...

The US Food and Drug Administration on Thursday approved the first gene therapy for inherited hearing loss, a one-time ...

After struggling to adapt through school and adult life, Lucy was offered a new procedure at Colchester Hospital. The mum-of-three went through a major surgery, making her the first person to have the ...

KOCHI: Four-year-old Angelo, hearing impaired since birth, had been living in complete silence. On Monday, his life changed, ...

The FDA has granted accelerated approval to Otarmeni™ (lunsotogene parvec-cwha), the first gene therapy for pediatric and adult patients with OTOF-related sensorineural hearing loss.

A teenager from south Essex with hearing loss is taking on the London Marathon after undergoing a "life-changing" surgery ...

That shift shows up in the hospital’s growth. In its first year alone, Driscoll RGV logged thousands of emergency visits, ...

Cochlear’s shock downgrade rattled the healthcare sector, with Scott Power warning structural headwinds are challenging the ...